There's still uncertainty about the big drugmaker's future COVID-19 vaccine revenue.Pfizer (NYSE: PFE) recently announced very good first-quarter results. Revenue and profits soared. The big drugmaker even raised its full-year guidance. However, its share price barely moved.In this Motley Fool Live ...

https://www.fool.com/investing/2021/05/14/why-pfizer-stock-didnt-soar-after-its-fantastic-q1/?source=iedfolrf0000001

#fool